000917071 001__ 917071
000917071 005__ 20240201205520.0
000917071 0247_ $$2doi$$a10.1007/s00259-022-05964-w
000917071 0247_ $$2ISSN$$a1619-7070
000917071 0247_ $$2ISSN$$a0340-6997
000917071 0247_ $$2ISSN$$a1432-105X
000917071 0247_ $$2ISSN$$a1619-7089
000917071 0247_ $$2Handle$$a2128/33575
000917071 0247_ $$2pmid$$a36102964
000917071 0247_ $$2WOS$$aWOS:000854732000001
000917071 037__ $$aFZJ-2023-00315
000917071 082__ $$a610
000917071 1001_ $$0P:(DE-HGF)0$$aKatzdobler, Sabrina$$b0
000917071 245__ $$aAdditive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome
000917071 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2023
000917071 3367_ $$2DRIVER$$aarticle
000917071 3367_ $$2DataCite$$aOutput Types/Journal article
000917071 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1706773644_9293
000917071 3367_ $$2BibTeX$$aARTICLE
000917071 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000917071 3367_ $$00$$2EndNote$$aJournal Article
000917071 520__ $$aPurposeEarly after [18F]PI-2620 PET tracer administration, perfusion imaging has potential for regional assessment of neuronal injury in neurodegenerative diseases. This is while standard late-phase [18F]PI-2620 tau-PET is able to discriminate the 4-repeat tauopathies progressive supranuclear palsy and corticobasal syndrome (4RTs) from disease controls and healthy controls. Here, we investigated whether early-phase [18F]PI-2620 PET has an additive value for biomarker based evaluation of 4RTs.MethodsSeventy-eight patients with 4RTs (71 ± 7 years, 39 female), 79 patients with other neurodegenerative diseases (67 ± 12 years, 35 female) and twelve age-matched controls (69 ± 8 years, 8 female) underwent dynamic (0–60 min) [18F]PI-2620 PET imaging. Regional perfusion (0.5–2.5 min p.i.) and tau load (20–40 min p.i.) were measured in 246 predefined brain regions [standardized-uptake-value ratios (SUVr), cerebellar reference]. Regional SUVr were compared between 4RTs and controls by an ANOVA including false-discovery-rate (FDR, p < 0.01) correction. Hypoperfusion in resulting 4RT target regions was evaluated at the patient level in all patients (mean value − 2SD threshold). Additionally, perfusion and tau pattern expression levels were explored regarding their potential discriminatory value of 4RTs against other neurodegenerative disorders, including validation in an independent external dataset (n = 37), and correlated with clinical severity in 4RTs (PSP rating scale, MoCA, activities of daily living).ResultsPatients with 4RTs had significant hypoperfusion in 21/246 brain regions, most dominant in thalamus, caudate nucleus, and anterior cingulate cortex, fitting to the topology of the 4RT disease spectrum. However, single region hypoperfusion was not specific regarding the discrimination of patients with 4RTs against patients with other neurodegenerative diseases. In contrast, perfusion pattern expression showed promise for discrimination of patients with 4RTs from other neurodegenerative diseases (AUC: 0.850). Discrimination by the combined perfusion-tau pattern expression (AUC: 0.903) exceeded that of the sole tau pattern expression (AUC: 0.864) and the discriminatory power of the combined perfusion-tau pattern expression was replicated in the external dataset (AUC: 0.917). Perfusion but not tau pattern expression was associated with PSP rating scale (R = 0.402; p = 0.0012) and activities of daily living (R =  − 0.431; p = 0.0005).Conclusion[18F]PI-2620 perfusion imaging mirrors known topology of regional hypoperfusion in 4RTs. Single region hypoperfusion is not specific for 4RTs, but perfusion pattern expression may provide an additive value for the discrimination of 4RTs from other neurodegenerative diseases and correlates closer with clinical severity than tau pattern expression.
000917071 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000917071 536__ $$0G:(DE-HGF)POF4-5254$$a5254 - Neuroscientific Data Analytics and AI (POF4-525)$$cPOF4-525$$fPOF IV$$x1
000917071 536__ $$0G:(DE-HGF)POF4-5251$$a5251 - Multilevel Brain Organization and Variability (POF4-525)$$cPOF4-525$$fPOF IV$$x2
000917071 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x3
000917071 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000917071 7001_ $$0P:(DE-HGF)0$$aNitschmann, Alexander$$b1
000917071 7001_ $$0P:(DE-HGF)0$$aBarthel, Henryk$$b2
000917071 7001_ $$0P:(DE-Juel1)166265$$aBischof, Gerard$$b3$$ufzj
000917071 7001_ $$0P:(DE-HGF)0$$aBeyer, Leonie$$b4
000917071 7001_ $$0P:(DE-HGF)0$$aMarek, Ken$$b5
000917071 7001_ $$0P:(DE-HGF)0$$aSong, Mengmeng$$b6
000917071 7001_ $$0P:(DE-HGF)0$$aWagemann, Olivia$$b7
000917071 7001_ $$0P:(DE-HGF)0$$aPalleis, Carla$$b8
000917071 7001_ $$0P:(DE-HGF)0$$aWeidinger, Endy$$b9
000917071 7001_ $$0P:(DE-HGF)0$$aNack, Anne$$b10
000917071 7001_ $$0P:(DE-HGF)0$$aFietzek, Urban$$b11
000917071 7001_ $$0P:(DE-HGF)0$$aKurz, Carolin$$b12
000917071 7001_ $$0P:(DE-HGF)0$$aHäckert, Jan$$b13
000917071 7001_ $$0P:(DE-HGF)0$$aStapf, Theresa$$b14
000917071 7001_ $$0P:(DE-HGF)0$$aFerschmann, Christian$$b15
000917071 7001_ $$0P:(DE-HGF)0$$aScheifele, Maximilian$$b16
000917071 7001_ $$0P:(DE-HGF)0$$aEckenweber, Florian$$b17
000917071 7001_ $$0P:(DE-HGF)0$$aBiechele, Gloria$$b18
000917071 7001_ $$0P:(DE-HGF)0$$aFranzmeier, Nicolai$$b19
000917071 7001_ $$0P:(DE-HGF)0$$aDewenter, Anna$$b20
000917071 7001_ $$0P:(DE-HGF)0$$aSchönecker, Sonja$$b21
000917071 7001_ $$0P:(DE-HGF)0$$aSaur, Dorothee$$b22
000917071 7001_ $$0P:(DE-HGF)0$$aSchroeter, Matthias L.$$b23
000917071 7001_ $$0P:(DE-HGF)0$$aRumpf, Jost-Julian$$b24
000917071 7001_ $$0P:(DE-HGF)0$$aRullmann, Michael$$b25
000917071 7001_ $$0P:(DE-HGF)0$$aSchildan, Andreas$$b26
000917071 7001_ $$0P:(DE-HGF)0$$aPatt, Marianne$$b27
000917071 7001_ $$0P:(DE-HGF)0$$aStephens, Andrew W.$$b28
000917071 7001_ $$0P:(DE-Juel1)169110$$avan Eimeren, Thilo$$b29
000917071 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b30$$ufzj
000917071 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b31$$ufzj
000917071 7001_ $$0P:(DE-HGF)0$$aDanek, Adrian$$b32
000917071 7001_ $$0P:(DE-HGF)0$$aClassen, Joseph$$b33
000917071 7001_ $$0P:(DE-HGF)0$$aBürger, Katharina$$b34
000917071 7001_ $$0P:(DE-HGF)0$$aJanowitz, Daniel$$b35
000917071 7001_ $$0P:(DE-HGF)0$$aRauchmann, Boris-Stephan$$b36
000917071 7001_ $$0P:(DE-HGF)0$$aStöcklein, Sophia$$b37
000917071 7001_ $$0P:(DE-HGF)0$$aPerneczky, Robert$$b38
000917071 7001_ $$0P:(DE-HGF)0$$aSchöberl, Florian$$b39
000917071 7001_ $$0P:(DE-HGF)0$$aZwergal, Andreas$$b40
000917071 7001_ $$0P:(DE-HGF)0$$aHöglinger, Günter U.$$b41
000917071 7001_ $$0P:(DE-HGF)0$$aBartenstein, Peter$$b42
000917071 7001_ $$0P:(DE-HGF)0$$aVillemagne, Victor$$b43
000917071 7001_ $$0P:(DE-HGF)0$$aSeibyl, John$$b44
000917071 7001_ $$0P:(DE-HGF)0$$aSabri, Osama$$b45
000917071 7001_ $$0P:(DE-HGF)0$$aLevin, Johannes$$b46
000917071 7001_ $$0P:(DE-HGF)0$$aBrendel, Matthias$$b47$$eCorresponding author
000917071 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-022-05964-w$$gVol. 50, no. 2, p. 423 - 434$$n2$$p423 - 434$$tEuropean journal of nuclear medicine and molecular imaging$$v50$$x1619-7070$$y2023
000917071 8564_ $$uhttps://juser.fz-juelich.de/record/917071/files/s00259-022-05964-w.pdf$$yOpenAccess
000917071 909CO $$ooai:juser.fz-juelich.de:917071$$pdnbdelivery$$popenaire$$pdriver$$pVDB$$popen_access
000917071 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166265$$aForschungszentrum Jülich$$b3$$kFZJ
000917071 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b30$$kFZJ
000917071 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b31$$kFZJ
000917071 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000917071 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5254$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x1
000917071 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5251$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x2
000917071 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x3
000917071 9141_ $$y2022
000917071 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-23
000917071 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000917071 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-23
000917071 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-23$$wger
000917071 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000917071 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2023-08-23
000917071 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000917071 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000917071 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-23
000917071 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-23
000917071 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000917071 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000917071 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-23
000917071 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-23
000917071 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2023-08-23
000917071 920__ $$lyes
000917071 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000917071 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x1
000917071 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x2
000917071 980__ $$ajournal
000917071 980__ $$aVDB
000917071 980__ $$aI:(DE-Juel1)INM-2-20090406
000917071 980__ $$aI:(DE-Juel1)INM-5-20090406
000917071 980__ $$aI:(DE-Juel1)INM-3-20090406
000917071 980__ $$aUNRESTRICTED
000917071 9801_ $$aFullTexts